Trials / Recruiting
RecruitingNCT06511752
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
Educational Support Group Program for Carepartners of Bilingual and Spanish-speaking Persons With Progressive Forms of Aphasia and for Persons With Progressive Forms of Aphasia
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- University of Texas at Austin · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation/communication skills training phase on measures of psychosocial function, communicative effectiveness and speech/language function. Analysis of study-specific surveys and semi-structured interviews will provide qualitative data regarding outcomes. Before beginning the education and support group, focus groups will be run in order to set priorities for the themes to be included in the education program. Participants will join via tele-based means if preferred and these participants may reside in the United States, or internationally including Mexico and Spain.
Detailed description
Two educational/support group routes will be offered: 1. Progressive aphasia (PA) educational/support group or 2. Caregiver educational support group with an implementation phase (including their partner with PA). The caregiver educational support group path will be delivered in two phases, whereas the PA educational support group path will only consist of the first phase. The first phase of the caregiver educational support group will focus on the educational support group and the second phase will consist of implementation and practice of strategies with feedback provided by the clinician. The educational/support groups (Routes 1 and 2) will include opportunities for discussion of issues related to language-led dementia or progressive aphasia (e.g., coping with changes in cognition and language, use of strategies for effective communication) and education regarding the disorder provided by relevant experts (e.g., speech-language pathologists, licensed professional counselors), separately for carepartners and individuals with progressive aphasia. The implementation phase (Route 2, only) will allow for practice of strategies and skills learned in the first phase. The total amount of time participants will be involved in the study will be 9 months, inclusive of follow-up. Phase 1. Timeline for the support group portion of the study: Participants will complete pre-treatment measures during a period of 1-2 weeks prior to their first meeting. After four months of twice monthly meetings, post-treatment measures will be completed within 1-2 weeks of treatment completion. Follow-up evaluation will take place at 3-months post-treatment. Phase 2. Timeline for the implementation/dyad training portion of the study: Post-treatment assessment from Phase 1 will serve as pre-treatment assessment for Phase 2. Treatment sessions will be held once weekly for 4 weeks, and post-treatment assessment will be completed within 1-2 weeks of phase 2 treatment completion. Follow-up evaluation will take place at 3-months post-treatment.
Conditions
- Alzheimer Disease
- Dementia
- Primary Progressive Aphasia
- Aphasia
- Progressive Aphasia
- Progressive Aphasia in Alzheimer's Disease
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Psychosocial educational, support group and implementation of strategies | Psychosocial educational, support group and implementation of strategies |
Timeline
- Start date
- 2024-05-21
- Primary completion
- 2030-05-01
- Completion
- 2030-12-01
- First posted
- 2024-07-22
- Last updated
- 2025-03-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06511752. Inclusion in this directory is not an endorsement.